Puretech presents data for lyt-200 targeting galectin-9 in preclinical leukemia cancer models at the 64th american society of hematology (ash) annual meeting

Boston--( business wire )--puretech health plc (nasdaq: prtc, lse: prtc) ("puretech" or the "company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today shared new data supporting the clinical potential of lyt-200, a fully human monoclonal antibody (mab) designed to inhibit the activity of galectin-9, as a therapeutic agent for the treatment of leukemia. the data were shared in a scientific poster presented at the american society of hematology (ash) 64th annual meeting. lyt-200 is a therapeutic candidate targeting galectin-9, which is expressed by tumors and immune cells and plays a key role in cancer treatment resistance. it is also in development as a treatment for a range of cancer indications with otherwise poor survival rates.
PRTC Ratings Summary
PRTC Quant Ranking